Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Rybelsus®, the only oral GLP-1 ...

Novo Nordisk's Rybelsus gets US FDA approval for CV risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event ...

Please provide your email address to receive an email when new articles are posted on . Acoramidis reduced cumulative CV outcomes vs. placebo in patients with cardiac amyloidosis. The curves separated ...